Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical device company that manufactures and sells surgical instruments and products for neurosurgery, neurocritical care, ear, nose, throat (ENT), and wound care. Its business is organized into two segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment offers neurosurgery and neurocritical care products such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, along with after-market services. It also provides surgical headlamps, instrumentation, and lighting products for hospitals, surgery centers, dental, podiatry, and veterinary offices. The Tissue Technologies segment focuses on wound care, including acute wound treatments like burns and chronic wound care such as diabetic foot ulcers, as well as surgical tissue repair applications like hernia reinforcement, tendon protection, and peripheral nerve repair. Additionally, the ENT business includes instrumentation, balloon technologies for sinus and eustachian tube dilation, and surgical navigation systems.

Integra LifeSciences Holdings Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IART. The company trades in U.S. dollars (USD), as it is headquartered in the United States. Being listed on a major U.S. exchange like NasdaqGS provides liquidity and visibility to investors worldwide. The stock is part of the Healthcare sector, specifically the Medical Devices industry, and is categorized under the US region.

Integra LifeSciences Holdings Corporation operates in the Healthcare sector and is classified under the Medical Devices industry. As a medical device company, it focuses on developing and manufacturing products used in surgical procedures, particularly in neurosurgery, neurocritical care, ear, nose, and throat (ENT) treatments, and wound care. The company's products include surgical instruments, implantable devices, and advanced wound care solutions. Its industry is highly regulated and competitive, with a focus on innovation and clinical efficacy. Integra's portfolio serves hospitals, surgery centers, and healthcare providers globally, addressing a wide range of medical needs from cranial stabilization to chronic wound management.

Integra LifeSciences Holdings Corporation is headquartered in the United States, as indicated by its country and region classification (US). The company serves a global market, offering its products directly through various salesforces and distribution channels to hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and healthcare providers worldwide. Its geographic reach includes both domestic and international markets, with a focus on neurosurgery, neurocritical care, ENT, and wound care. The company's products are used in a variety of clinical settings, from acute care hospitals to outpatient surgery centers, and it maintains a presence in multiple regions to support its diverse customer base.

Integra LifeSciences generates revenue through the sale of medical devices and surgical instruments across two main business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment contributes revenue from neurosurgery and neurocritical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also earns from after-market services and sales of surgical headlamps, instrumentation, and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. The Tissue Technologies segment generates revenue from wound care products for acute and chronic wounds, such as burns and diabetic foot ulcers, as well as surgical tissue repair applications like hernia reinforcement, tendon protection, and peripheral nerve repair. Additionally, the ENT business adds revenue from instrumentation, balloon technologies for sinus and eustachian tube dilation, and surgical navigation systems. The company sells directly through its salesforces and via distribution channels to healthcare providers globally.